+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in the treatment of rheumatoid arthritis

Recent advances in the treatment of rheumatoid arthritis

Current Opinion in Rheumatology 30(3): 231-237

Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017. In aggregate, the sarilumab studies show that it is effective in RA, including patients with incomplete responses to methotrexate and anti-tumor necrosis factor inhibitor, and showing superior efficacy when used in higher dose (200 mg every 2 weeks) to standard-dose adalilumab. Other drugs that are currently being studied include the IL-6 cytokine blocker sarikumab, the small targeted molecule filgotinib, and many new biosimilars. Baracitinib failed to achieve approval by the Food and Drug Administration primarily over perceived safety concerns. The two biosimilar drugs currently approved are CT-P13 and SB2, which are based on the reference product infliximab. Although this review summarizes trials examining biologic tapering, additional data are needed to guide clinicians in regards to treatment de-escalation in RA. With the greatly expanded armamentarium of RA treatment options available, it is important for clinicians to understand the data regarding drug efficacy and safety. With remission increasingly attainable, effective drug tapering strategies are needed. Although tapering trials do exist, more studies will be needed to help guide clinical practice.

(PDF emailed within 0-6 h: $19.90)

Accession: 065462738

Download citation: RISBibTeXText

PMID: 29461286

DOI: 10.1097/BOR.0000000000000496

Related references

Recent advances in the treatment of rheumatoid arthritis. Postgraduate Medical Journal 26(298): 447-451, 1950

Recent advances in the treatment of rheumatoid arthritis. Clinical Cornerstone 2(2): 38-50, 2000

Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus. Clinical and Experimental Dermatology 30(2): 201-204, 2005

Recent therapeutic advances in the treatment of rheumatoid arthritis. North Carolina Medical Journal 68(6): 425-426, 2008

Recent advances in the hormonal treatment of rheumatoid arthritis. Revista Clinica Espanola 35(6): 409-414, 1949

Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomaterials Science 5(8): 1407-1420, 2017

Recent advances in the surgical treatment of rheumatoid arthritis. Clinical Orthopaedics and Related Research 1990(258): 62-72, 1990

Recent practical advances in the medical treatment of rheumatoid arthritis. Journal de Medecine de Strasbourg 23(7): 374-376, 1992

Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opinion on Drug Delivery 2019, 2019

Rheumatoid arthritis: a review of recent advances in our knowledge concerning pathology, diagnosis, and treatment. Journal of Chronic Diseases 1(2): 168-210, 1955

Recent Advances in the Rehabilitation of Rheumatoid Arthritis; Rheumatoid Factor. Maryland State Medical Journal 14: 117-119, 1965

Recent advances in rheumatoid arthritis. Postgraduate Medical Journal 86(1014): 243-250, 2010

Recent advances in rheumatoid arthritis. New York State Journal of Medicine 57(21): 3489-3499, 1957

Recent advances in the pathogenesis of rheumatoid arthritis. Clinical Calcium 19(3): 303-309, 2009

Recent advances in the genetics of rheumatoid arthritis. Current Opinion in Rheumatology 22(2): 109-118, 2010